Stratec aligns diagnostics strategy, shares on SDAX radar

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 12:06.

Stratec (DE000STRA555) continues to position itself as a specialist in in-vitro diagnostics platforms with a long-term partnership model. The SDAX-listed company competes in the European medtech space alongside names such as Siemens Healthineers and Sartorius.

Stratec's diagnostics focus

Stratec develops and produces fully integrated analyzer systems and smart consumables for in-vitro diagnostics and life sciences companies, following a so-called OEM model where partners own the end customer relationship.

The group typically enters multi-year development and supply agreements under which it designs instrument platforms that partners brand and market globally, creating recurring revenue streams from installed bases.

Positioning among medtech peers

In the German-listed medtech peer group, Stratec operates at a smaller scale than Siemens Healthineers and Fresenius Medical Care, but shares a focus on diagnostic and clinical workflows that are critical for hospital and laboratory operations.

Analyst and market commentary on European medtech regularly references the importance of automation and integration in laboratory environments, a niche where Stratec's platform approach is designed to fit.

The product behind the stock

One representative Stratec platform is the random-access immunoassay analyzer, designed to run automated blood tests for parameters such as cardiac markers or infectious diseases. These instruments are tailored and branded by partner companies that supply them to laboratories worldwide.

Where the stock trades today

The Stratec shares (DE000STRA555) trade on Xetra; a recent quotation was not reliably verifiable, so the latest price level cannot be stated here with precision.

Disclaimer: This text is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. All data and statements are based on sources believed to be reliable but cannot be guaranteed.